Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.46 |
| ▸ | THRB | P10828 | 8/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14844930 | 0.90 | TGFBR1 (0.56) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL18115036 | 0.86 | TGFBR1 (0.47) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL29994161 | 0.85 | THRB (0.58) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL14845042 | 0.85 | THRB (0.58) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL2524801 | 0.82 | THRB (0.54) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL18115041 | 0.81 | TGFBR1 (0.48) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL18114936 | 0.78 | TGFBR1 (0.54) | TGFBR1THRBMAP3K20GRM2 | |
| SCHEMBL18115102 | 0.78 | TGFBR1 (0.44) | TGFBR1THRBTGFBR2MAP3K20MAPK14 | |
| SCHEMBL18114988 | 0.76 | TGFBR1 (0.46) | TGFBR1THRBTGFBR2MAP3K20CYP2D6 | |
| SCHEMBL18115001 | 0.76 | TGFBR1 (0.48) | TGFBR1THRBTGFBR2MAP3K20MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763993-B1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER IP GMBH (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-9314026-B2 | Heterocyclylpyri(mi)dinylpyrazole | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| EP-2763993-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | Bayer Intellectual Property GmbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050434-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | H1-0, NQO2, CCNI | TGFBR1 1833/4885THRB 4167/4885MET 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.